Table 6. Sensitivity Analyses for the Primary Efficacy Outcome by Diabetes Type, Age, and Follow-Up Duration.
| Intervention | Overall SUCRA rank* | SUCRA rank for type 2 diabetes only* | SUCRA rank for aged 40+ only* | SUCRA rank for 12+ months follow-up only* |
|---|---|---|---|---|
| ACEI | - | 7 | 6 | - |
| ACEI+amlodipine | - | 26 | 2 | - |
| Amlodipine | 13 | 6 | - | - |
| Amlodipine+fosinopril | 5 | 21 | - | 6 |
| Benazepril | - | 20 | 1 | 7 |
| Benazepril+amlodipine | - | 4 | - | 3 |
| Candesartan | 4 | - | 7 | - |
| Candesartan+HCTZ | - | 15 | 3 | - |
| Candesartan+lisinopril | - | 28 | - | - |
| Candesartan+manidipine | - | 5 | 7 | - |
| Captopril | 6 | 10 | 4 | 1 |
| Captopril+diltiazem | 1 | 27 | - | 14 |
| Enalapril | 12 | 24 | 4 | 15 |
| Enalapril+losartan | 10 | 11 | - | 11 |
| Fosinopril | 8 | 8 | 2 | 5 |
| Lisinopril | 14 | 16 | - | 13 |
| Lisinopril+losartan | 15 | 17 | - | 8 |
| Lisinopril+telmisartan† | 18 | 14 | 5 | - |
| Losartan | 9 | 18 | - | 11 |
| Losartan+HCTZ | - | 12 | 8 | 10 |
| Manidipine | 19 | 23 | 6 | 6 |
| Manidipine+delapril | - | 25 | - | 9 |
| Nifedipine | 22 | 12 | - | - |
| Nitrendipine | 21 | 19 | - | - |
| Perindopril | - | 15 | - | 10 |
| Perindopril+indapamide | - | - | - | 2 |
| Ramipril | 23 | 2 | - | 4 |
| Spironolactone | 24 | 3 | - | - |
| Tangshen formula | 7 | 1 | - | - |
| Telmisartan | 20 | 9 | 3 | - |
| Telmisartan+lisinopril† | 17 | 22 | - | - |
| Telmisartan+TCMZ | - | 13 | - | - |
| Telmisartan+TCMZ+amlodipine | - | 29 | - | - |
| Trandolapril | 3 | - | - | - |
| Trandolapril+candesartan | 2 | - | - | - |
| Valsartan | 11 | - | - | 12 |
| Valsartan+amlodipine+canrenone | - | - | - | - |
| Valsartan+amlodipine+HCTZ | - | - | - | - |
*Placebo was ranked 16th in the overall analysis, was ranked 30th in the type 2 diabetes analysis, was ranked 9th in the aged 40+ analysis, and was ranked 16th in the 12+ months follow-up analysis.
†Lisinopril+telmisartan refers to lisinopril+telmisartan combination therapy following lisinopril monotherapy, while telmisartan+lisinopril refers to lisinopril+telmisartan combination therapy following telmisartan monotherapy.